Two new alkaloids from the roots of Stemona parviflora

IF 1.3 4区生物学 Q4 CHEMISTRY, MEDICINAL

Phytochemistry Letters Pub Date : 2025-05-19 DOI:10.1016/j.phytol.2025.102993

Si-Wei Luo, Qi-Fan Xu, Zhi-Qi Yin, Ke Pan

引用次数: 0

Abstract

Two previously undescribed stemofoline alkaloids, 11(E)-oxystemofoline (1) and 11(E)-17-hydroxystemofoline (2), and three known compounds, 11(E)-2′(S)-hydroxystemofoline (3), stemofoline (4), and isostemofoline (5), were isolated from the roots of Stemona parviflora. Their structures were elucidated by spectroscopic data analysis and single-crystal X-ray diffraction. 2 has unprecedented hydroxylation at C-17 of the stemofoline alkaloid skeleton. The inhibitory effects of all isolates on LPS-induced NO production in RAW 264.7 cells were evaluated. Although only 4 was active, the results showed that the Z configuration of the Δ¹¹ double bond was potentially beneficial for the anti-inflammatory effect of stemofoline alkaloids.

查看原文本刊更多论文

从小檗根中提取的两个新的生物碱

两种先前未被描述的stemofoline生物碱，11(E)-氧系统ofoline(1)和11(E)-17-羟基系统ofoline(2)，以及三种已知的化合物，11(E)-2 ' (S)-羟基系统ofoline (3), stemofoline(4)和isostemofoline(5)，都是从小植物Stemona parviflora的根中分离出来的。通过光谱数据分析和单晶x射线衍射对其结构进行了表征。2在茎黄碱生物碱骨架的C-17处发生了前所未有的羟基化。观察各分离物对lps诱导的RAW 264.7细胞NO生成的抑制作用。虽然只有4具有活性，但结果表明Δ11双键的Z构型可能有利于stemofoline生物碱的抗炎作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Phytochemistry Letters 生物-生化与分子生物学

CiteScore

3.00

自引率

11.80%

发文量

190

审稿时长

34 days

期刊介绍： Phytochemistry Letters invites rapid communications on all aspects of natural product research including: • Structural elucidation of natural products • Analytical evaluation of herbal medicines • Clinical efficacy, safety and pharmacovigilance of herbal medicines • Natural product biosynthesis • Natural product synthesis and chemical modification • Natural product metabolism • Chemical ecology • Biotechnology • Bioassay-guided isolation • Pharmacognosy • Pharmacology of natural products • Metabolomics • Ethnobotany and traditional usage • Genetics of natural products Manuscripts that detail the isolation of just one new compound are not substantial enough to be sent out of review and are out of scope. Furthermore, where pharmacology has been performed on one new compound to increase the amount of novel data, the pharmacology must be substantial and/or related to the medicinal use of the producing organism.